Physician profile
Miranda Rosenberg
NPI 1437685385
$8,130.68
in general payments reported to CMS, 2019-2025
34 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2021: $592 · 2022: $988 · 2023: $2,814 · 2024: $1,327 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,104 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,104.40 |
| Education | $264.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imbed Biosciences INC. | $1,021.24 | 2023 | |
| Abbvie INC. | $939.35 | 2019-2025 | Skyrizi |
| Sun Pharmaceutical Industries INC. | $841.67 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Allergan, INC. | $672.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $663.20 | 2019-2023 | Dupixent, Libtayo |
| Amgen INC. | $389.79 | 2019-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.90 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $362.74 | 2023-2024 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $361.82 | 2023-2024 | Clear+Brilliant |
| Galderma Laboratories, L.P. | $321.33 | 2021-2023 | Dysport |
| Janssen Biotech, INC. | $285.32 | 2021-2023 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $263.64 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $233.82 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $162.19 | 2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $132.05 | 2023 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $130.00 | 2019 | |
| Organon LLC | $118.48 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $117.67 | 2021 | |
| Journey Medical Corporation | $96.18 | 2025 | |
| Hill Dermaceuticals, INC. | $82.84 | 2024 | Tolak |
| Biofrontera INC. | $69.58 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $66.53 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Revance Therapeutics, INC. | $64.20 | 2025 | Daxxify |
| Kerecis Limited | $61.50 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $50.75 | 2023-2024 | Puraply, Cygnus Dual |
| Genzyme Corporation | $48.44 | 2019-2022 | |
| Merz North America, INC. | $31.33 | 2021 | |
| Icad, INC | $28.52 | 2022 | |
| Fresenius Kabi USA, LLC | $27.86 | 2023 | |
| Mayne Pharma Commercial LLC | $24.06 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.20 | 2024 | |
| Tempus Ai, INC | $21.34 | 2024 | Merlin Test |
| Botanix Sb INC | $19.20 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.09 | 2023 | Jublia, Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.